Tenaya Therapeutics, Inc. (TNYA) stock
TNYANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.32−0.01 (-3.24%)
Close on Nov 17, 2026Market cap $72.38MP/E –Yield –
Tenaya Therapeutics cash
Cash and short-term investments held at the end of each period.
Tenaya Therapeutics's cash was $78.10M at Jun 30, 2026. For fiscal 2025 it was $100.50M, up 63.7% from the year before. The highest annual figure on record is $251.30M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $100.50M | +63.7% |
| FY2024 | Dec 31, 2024 | $61.40M | -41.3% |
| FY2023 | Dec 31, 2023 | $104.60M | -48.8% |
| FY2022 | Dec 31, 2022 | $204.20M | -18.7% |
| FY2021 | Dec 31, 2021 | $251.30M | +95.5% |
| FY2020 | Dec 31, 2020 | $128.54M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $78.10M | +8.9% |
| Q1 FY2026 | Mar 31, 2026 | $80.90M | -8.3% |
| Q4 FY2025 | Dec 31, 2025 | $100.50M | +63.7% |
| Q3 FY2025 | Sep 30, 2025 | $56.30M | -29.2% |
| Q2 FY2025 | Jun 30, 2025 | $71.70M | -27.8% |
| Q1 FY2025 | Mar 31, 2025 | $88.20M | -27.8% |
| Q4 FY2024 | Dec 31, 2024 | $61.40M | -41.3% |
| Q3 FY2024 | Sep 30, 2024 | $79.50M | -37.9% |
| Q2 FY2024 | Jun 30, 2024 | $99.30M | -34.5% |
| Q1 FY2024 | Mar 31, 2024 | $122.20M | -29.6% |
| Q4 FY2023 | Dec 31, 2023 | $104.60M | -48.8% |
| Q3 FY2023 | Sep 30, 2023 | $128.10M | -14.3% |
| Q2 FY2023 | Jun 30, 2023 | $151.60M | -16.2% |
| Q1 FY2023 | Mar 31, 2023 | $173.60M | -18.7% |
| Q4 FY2022 | Dec 31, 2022 | $204.20M | -18.7% |
| Q3 FY2022 | Sep 30, 2022 | $149.50M | -46.7% |
| Q2 FY2022 | Jun 30, 2022 | $180.90M | +61.7% |
| Q1 FY2022 | Mar 31, 2022 | $213.50M | +66.2% |
| Q4 FY2021 | Dec 31, 2021 | $251.30M | +95.5% |
| Q3 FY2021 | Sep 30, 2021 | $280.50M | +357.3% |
| Q2 FY2021 | Jun 30, 2021 | $111.89M | +177.4% |
| Q1 FY2021 | Mar 31, 2021 | $128.44M | – |
| Q4 FY2020 | Dec 31, 2020 | $128.54M | – |
| Q3 FY2020 | Sep 30, 2020 | $61.34M | – |
| Q2 FY2020 | Jun 30, 2020 | $40.34M | – |
See a number that looks wrong?